Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Leuk Lymphoma. 2022 Mar 8;63(7):1566–1579. doi: 10.1080/10428194.2022.2043299

Figure 2. Lenalidomide enhances transcriptional signatures related to T-cell function.

Figure 2.

The heat maps and dendrograms of unsupervised hierarchical clustering display differentially expressed genes between NT and CD23.CAR+ T lymphocytes obtained from CLL donor #1, treated in vitro with lenalidomide or left untreated. The gene expression differences among the samples were functionally classified as follows: (A) Th1; (B) costimulatory molecules; (D) interleukin signaling; (F) T-cell exhaustion; (G) T-cell migration; (H) memory markers. Fold changes between lenalidomide (+L) and untreated (-L) sample for costimulatory molecules (C) and interleukin signaling (E) are represented with box and whisker plots.